[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"community-acquired-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:community-acquired-pneumonia":93},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,45,77,107,137,161,186,218,245,271,296,326,349,371,393,424,455,479,504,534,560,582,608,633,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100605562","phase-4-azithromycin-versus-doxycycline-in-hospitalized-adult-patients-with-community-acquired-pneumonia-treated-with-beta-lactams-100605562",false,"NCT07164131","Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams","AD-CAP","Inclusion Criteria:\n\n• All adult patients (\\>18 years old) admitted with CAP and receiving a beta-lactam antibiotic plus a form of atypical coverage (azithromycin or doxycycline) in the ED within 12 hours of admission.\n\nExclusion Criteria:\n\n* High clinical suspicion for Legionella pneumonia\n* Allergy or contraindication to the use of either azithromycin or doxycycline (usual clinical practice)\n* Antibiotics not for CAP\n* Pregnant women (based on clinical assessment as part of standard of care)\n* Severe CAP as defined by the ATS\u002FIDSA criteria\n* Corrected QT prolongation (\\> 440 ms in men and \\> 460 ms in women)\n* Receiving a different antibiotic (e.g quinolones)\n* Admission \\> 24 hours\n* Known to be a prisoner","ALL","18 Years",{"count":20,"type":21},1120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to compare effectiveness and safety of Azithromycin versus Doxycycline in adult patients hospitalized with community acquired pneumonia (CAP) treated with Beta-lactams.",[27],"Community-acquired Pneumonia",[29,30,31],"Azithromycin","Doxycycline","hospitalized","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-09-15",{"date":40,"type":21},"2031-09-01",{"name":42,"class":43},"Mayo Clinic","OTHER",5,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100645117","community-acquired-pneumonia-due-to-chlamydia-pneumoniae-100645117","NCT07679789","Community-acquired Pneumonia Due to Chlamydia Pneumoniae","Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR","CHLAMPAC","Inclusion Criteria:\n\n* Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.\n* Availability of clinical data allowing confirmation of pneumonia diagnosis.\n\nExclusion Criteria:\n\n* Patient opposition to the use of medical data for research purposes.\n* Absence of pneumonia diagnosis.\n* Insufficient clinical data for analysis.",{"count":54,"type":21},200,"OBSERVATIONAL","This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.\n\nThe working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.\n\nThe primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.\n\nSecondary objectives include;\n\n1. Outpatient management\n2. Hospitalization in a medical ward\n3. Admission to the intensive care unit\n4. In-hospital mortality\n5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae\n6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP",[58],"Community-Acquired Pneumonia",[60,61,62,63,64,65,66],"Chlamydia pneumoniae","Community-acquired pneumonia","Prevalence","PCR","Co-infection","Respiratory infection","Atypical pneumonia","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":36},{"date":71,"type":21},"2026-06",{"date":73,"type":21},"2027-06",{"name":75,"class":43},"Centre Hospitalier de Saint-Denis",1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":76},"100642506","early-phase-1-3-vs-5-days-of-amoxicillin-for-childhood-pneumonia-an-rct-100642506","NCT07647835","3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT","Comparison 0f 03days Vs 05days Amoxicillin In Uncomplicated Community Acquired Pneumonia In Children. A Randomized Controlled Trial","Pnemonia","Inclusion criteria:\n\n* Age; ≥ 3 months to 5 years\n* Fever; recorded temperature of ≥100.4 f or guardian reported fever within 2 days\n* Cough; observed or reported within 3 days\n* Tachypnea;\n* 3 months to 1 years ≥ 50 breaths per minute\n* 1 years to 5 years ≥ 40 breaths per minute\n* C- reactive protein ≥ 40\n* White blood cells ≥ 12200\n* Chest X-ray;\n* Presence of a dense opacity occupying a portion or whole of lobe with or without air Broncho grams.\n\nExclusion criteria:\n\n* Patient who is Lethargic and unable to tolerate orally.\n* Capillary refill greater than 2 second\n* Chronic lung disease\n* Congenital heart disease or sickle cell anemia patient\n* Immunocompromised patient\n* malnourished\n* Known or suspected tuberculosis patient\n* Patient has used prior antibiotic within 2 days\n* Allergic to penicillin or amoxicillin\n* C-reactive protein greater than 72\n* White blood cells greater than 25000\n* Chest x rays show linear or patchy or peri bronchial opacity\n* Presence of pleural effusions\n* Empyema, lung abscess, necrotizing pneumonia or pneumatocele\n* Other alternative diagnosis like wheezing syndrome (Bilateral wheezing on auscultation)","3 Months","5 Years",{"count":88,"type":21},250,[90],"EARLY_PHASE1","Pneumonia is the most common infection in children and leading to most common cause of mortality and morbidity in in children globally. Bacterial cause is mostly streptococcus pneumonia in children of 3 months to 5 years of age. Traditionally 7-10 antibiotic is used for uncomplicated community acquired pneumonia. World health organization (WHO) recommends 5 days of antibiotic for non-severe pneumonia with oral amoxicillin while National institute for health and care excellence (NICE) guidelines 2025 recommends 3-days course of amoxicillin in uncomplicated community acquired pneumonia.1,2 Most studies show Short course antibiotic is as effective as long course of antibiotic with fewer side effect. The Khyber Pakhtunkhwa province faces particular challenges due to limited healthcare access, malnutrition, and suboptimal vaccination coverage which leads to major burden of pneumonia in less than 5 years' children.7 There is need of local data about effectiveness of short course antibiotic in uncomplicated community acquired pneumonia. 3-day oral amoxicillin has better compliance and less side effect of medicine. Short course of oral amoxicillin is cost effective as pneumonia is more common in low socioeconomic population and 3-day course antibiotic is more economical and has better compliance. Long course of antibiotic leads to antibiotic resistance and adverse effects like diarrhea and other gastrointestinal symptoms.",[93,94],"Community Acquired Pneumonia","Childhood Pneumonia",[96,97],"Amoxcillin in childhood pneumonia","community acquired pneumonia","2026-06-09",{"date":100,"type":36},"2026-06-15",{"date":102,"type":21},"2026-06-01",{"date":104,"type":21},"2027-06-01",{"name":106,"class":43},"Khyber Teaching Hospital",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":55,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":76},"100219833","epidemiological-study-on-community-acquired-pneumonia-100219833","NCT02139163","Epidemiological Study on Community Acquired Pneumonia","CAPNETZ","Inclusion Criteria:\n\n* age ≥ 18\n* infiltrate on chest X-ray\n* further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever\n\nExclusion Criteria:\n\n* Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia\n* Newly diagnosed, active pulmonary tuberculosis within the last 2 months",{"count":115,"type":21},20000,"6 Months","The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.",[93],[120,121,112,122,123,124,125,126,127],"Community acquired pneumonia","CAP","age ≥18","infiltrate on chest X-ray","cough or production of purulent sputum","pathologic lung auscultation","fever","adults","2026-04-29",{"date":130,"type":36},"2026-05-05",{"date":132,"type":4},"2002-10",{"date":134,"type":21},"2028-06",{"name":136,"class":43},"Capnetz Stiftung",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100590353","awake-prone-positioning-of-patients-suffering-community-acquired-pneumonia-requiring-nasal-high-flow-therapy-100590353","NCT06966310","Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy","Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy, Excluding COVID-19","PRONECAP","Inclusion Criteria:\n\n* Adult patients admitted to an intensive care unit or intermediate care unit\n* Suspicion of community acquired pneumonia (at least one of the 3 criteria): fever, cough, purulent expectoration\n* And abnormalities suggestive of pneumonia by chest X-ray or CT-scan\n* PaO2\u002FFiO2 ratio \\\u003C300 mmHg (or equivalent SpO2\u002FFiO2 i.e. \\\u003C 315 mmHg) under a minimum gas flow of 30 L\u002Fmin.\n* Person affiliated to a French social security system or equivalent\n* Informed consent.\n\nExclusion Criteria:\n\n* Positive SARS-COV2 test within the last 30 days\n* Indication for immediate intubation\n* Patients for whom a \"do not intubate\" decision has been made\n* Chest trauma or other contraindication to prone position\n* Patients with formal indication for non-invasive ventilation: exacerbation of chronic obstructive pulmonary disease, acute cardiogenic pulmonary oedema.\n* Pregnant or breastfeeding woman\n* Subjects who are under legal protection measure\n* More than 8h awake prone positioning prior to inclusion\n* More than 48h since intensive care unit or intermediate care unit admission.",{"count":146,"type":21},1078,[148],"NA","Community acquired pneumonia, in particular when requiring oxygen therapy because of acute hypoxemic respiratory failure and meeting acute respiratory distress syndrome (ARDS) criteria frequently leads to tracheal intubation and poor outcome.\n\nAmong invasively mechanically ventilated patients with ARDS and presenting a PaO2\u002FFiO2 ratio (arterial partial pressure of oxygen to inspired fraction of oxygen) of less than 150 mmHg, the prone position significantly reduces mortality and represents standard care (Guérin 2013). Among non-intubated COVID-19 patients, a subtype of viral community acquired pneumonia, a recent study showed that awake prone positioning reduces the composite outcome of intubation or death among patients requiring nasal high flow therapy. Furthermore, it favored weaning of nasal high flow therapy.\n\nProne position in patients with non-COVID ARDS treated with high nasal flow was evaluated in 20 patients with predominantly viral pneumonia (Ding 2020) and was associated with improved oxygenation.\n\nCoordinating investigator hypothesize that prone positioning of patients suffering non-COVID community acquired pneumonia and undergoing nasal high flow therapy can significantly improve outcome by reducing the need for intubation and associated therapies such as sedation and muscle relaxation.",[27],"2026-04-28",{"date":153,"type":36},"2026-05-04",{"date":155,"type":36},"2025-11-30",{"date":157,"type":21},"2034-10",{"name":159,"class":43},"University Hospital, Tours",38,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":76},"100592700","noninvasive-support-methods-for-acute-respiratory-failure-of-community-acquired-pneumonia-100592700","NCT06996834","Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia","A Randomized Controlled Trial of High-Velocity Nasal Insufflation (HVNI) Versus Noninvasive Ventilation (NIV) for Acute Respiratory Failure of Community-Acquired Pneumonia (CAP).","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical and radiographic diagnosis of CAP\n* Respiratory failure using partial pressure of oxygen (PaO₂) and fraction of inspired oxygen (FiO₂) is defined by a partial pressure of oxygen\u002Ffraction of inspired oxygen ratio (PaO₂\u002FFiO₂) ≤ 300 mmHg or a respiratory rate (RR) ≥ 25\u002Fmin\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Hemodynamic instability requiring vasopressors\n* Altered mental status Glasgow Coma Scale (GCS \\\u003C 13)\n* Contraindication to NIV or HVNI (facial trauma, recent upper airway surgery)\n* Do-Not-Intubate (DNI) order",{"count":169,"type":21},100,[148],"This randomized controlled trial aims to compare the efficacy and safety of high-velocity nasal insufflation (HVNI) versus standard noninvasive ventilation (NIV) in adult patients experiencing acute exacerbations of community-acquired pneumonia (CAP) accompanied by hypoxemic respiratory failure. The primary focus is on assessing treatment failure within 48 hours, defined as the need for intubation or death. Secondary outcomes include evaluations of gas exchange parameters, patient comfort levels, duration of ICU stay, and 28-day mortality rates.",[27,173],"Community-Acquired Infections",[121,175,176],"NIV","HVNI","2026-04-26",{"date":179,"type":36},"2026-04-30",{"date":181,"type":36},"2025-07-01",{"date":183,"type":21},"2026-11-01",{"name":185,"class":43},"Assiut University",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100504469","phase-3-antithrombotic-therapy-to-ameliorate-clinical-complications-in-community-acquired-pneumonia-100504469","NCT05848713","AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","ATTACC-CAP","Inclusion Criteria:\n\n1. Patients ≥18 years of age\n2. Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:\n\n   1. Radiographic evidence of new or worsening infiltrate\n   2. One or more of the following signs and\u002For symptoms of lower respiratory tract infection\n\n   i. New or increased cough or sputum production ii. Fever of \\> 37.8C or temperature \\\u003C 36C iii. WBC \\> 11 x 109\u002FL or \\\u003C 4 x 109\u002FL c. The primary diagnosis is believed to be CAP as per the attending physician\n3. Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)\n4. Hospital admission anticipated to last ≥72 hours from randomization\n\nExclusion Criteria:\n\n1. Suspected or confirmed active COVID-19 infection\n2. Hospital admission for \\>72 hours prior to randomization\n3. Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment\n4. Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization\n5. Patients for whom the intent is to not use pharmacologic thromboprophylaxis\n6. Patients with an independent indication for therapeutic-dose anticoagulation\n7. Patients with a contraindication to therapeutic-dose anticoagulation, including:\n\n   1. Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission\n   2. History of an inherited or acquired bleeding disorder\n   3. Cerebral aneurysm or mass lesions of the central nervous system\n   4. Ischemic stroke within 3 months of hospital admission\n   5. Gastrointestinal bleeding within 3 months of hospital admission\n   6. Platelet count \\\u003C50 x109\u002FL OR INR \\>2.0 OR hemoglobin \\\u003C80 g\u002FL at the time of screening\n   7. Other physician-perceived contraindications to therapeutic anticoagulation\n8. History of heparin induced thrombocytopenia (HIT) or other heparin allergy\n9. Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)\n10. Patients in whom imminent death is anticipated\n11. Anticipated transfer to another hospital that is not a study site within 72 hours of randomization\n12. Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization",{"count":194,"type":21},4000,[196],"PHASE3","This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).",[27],[200,201,202,120,203,204,205,206,207],"Pneumonia","Heparin","Anticoagulation","Unfractionated Heparin","Low Molecular Weight Heparin","Dalteparin","Enoxaparin","Tinzaparin","2026-04-16",{"date":210,"type":36},"2026-04-21",{"date":212,"type":36},"2023-10-10",{"date":214,"type":21},"2029-03-31",{"name":216,"class":43},"University of Manitoba",64,{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100533705","phase-3-amoxicillin-alone-versus-amoxicillinclavulanate-for-community-acquired-pneumonia-in-patients-aged-65-years-or-older-and-hospitalized-in-a-non-intensive-care-unit-ward-100533705","NCT06229288","Amoxicillin Alone Versus Amoxicillin\u002FClavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","Amoxicillin Alone Versus Amoxicillin\u002FClavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward: a Non-inferiority Randomized Controlled Trial","CAPTAIN","Inclusion Criteria:\n\n1. Patient aged 65 years or older with or without comorbidities defined by chronic diseases in immunocompetent patients,\n2. Patient admitted to the hospital for a CAP defined by at least two clinical signs of pneumonia (cough, sputum production, dyspnea, tachypnea, or pleuritic pain, abnormal lung auscultatory sounds, fever (temperature \\> 38°C) or hypothermia (\\\u003C36°C)), and had radiological evidence of a new infiltrate confirming pneumonia\n3. Patient understanding oral and written French\n4. Written informed consent obtained from patient prior to participation in the study (if the patient is unable to express in writing: consent by a trusted person).\n5. Patients should be able to call and to answer to a phone call or to be with a relative who can help him to call or to answer questions notably raised by a medical staff belonging to the investigational site\n\nExclusion Criteria:\n\n1. Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency, ICU admission)\n2. Patient requiring ICU admission,\n3. Estimated Glomerular Filtration Rate \\\u003C 30 ml\u002Fmin,\n4. Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4\\\u003C200\u002Fmm3),\n5. Exacerbation of chronic obstructive pulmonary disease,\n6. Life-threatening state expected to lead to possible imminent death,\n7. Suspected atypical bacteria requiring combined antibiotics therapy,\n8. Legionella suspected,\n9. Subjects with clinical or epidemiological environment leading to suspect a healthcare associated pneumonia with antibiotic resistant pathogen (including long-term care facility)\n10. Patient known to be colonized with Pseudomonas aeruginosa or Enterobacteriaceae in the respiratory tract,\n11. Suspicion of aspiration pneumonia,\n12. Administration of any antibiotic treatment for more than 24 hours before inclusion,\n13. History of jaundice\u002Fhepatic impairment associated with amoxicillin\u002Fclavulanate acid,\n14. History of bacterial pneumonia less than 1 month prior to study inclusion\n15. History of hypersensitivity or allergy to beta-lactam or to any excipients included in study antibiotics,\n16. Subject without health insurance,\n17. Subject without home address or difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation),\n18. Patient under judicial protection,\n19. Diagnosis confirmed of SAR-Cov2 infection (PCR Test, covid antigen rapid test, chest computed tomography (CT) scan),\n20. Participation to another interventional study and having an exclusion period that is still in force during the screening phase or expected participation to another interventional study during participation to the CAPTAIN study","65 Years",{"count":228,"type":21},326,[196],"Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions.\n\nIn the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies.\n\nPatients aged 65 years or older are often treated with amoxicillin\u002Fclavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.",[27],[61,233,234],"Amoxicillin","Amoxicillin\u002Fclavulanate","2026-04-02",{"date":237,"type":36},"2026-04-08",{"date":239,"type":36},"2024-04-25",{"date":241,"type":21},"2027-05-25",{"name":243,"class":43},"Nantes University Hospital",19,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":270},"100494804","phase-3-efficacy-and-safety-of-trimodulin-bt588-in-subjects-with-severe-community-acquired-pneumonia-scap-100494804","NCT05722938","Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)","A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)","ESsCAPE","Main Inclusion Criteria:\n\n1. Written informed consent.\n2. Hospitalized, adult (≥ 18 years of age) subject.\n3. Signs of inflammation based on C-reactive protein threshold level.\n4. Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission.\n5. Radiological (or other imaging technology) evidence consistent with active pneumonia.\n6. Acute respiratory failure requiring IMV.\n\nMain Exclusion Criteria:\n\n1. For an incapacitated subject: any indication that the subject's presumed will would be against inclusion in the trial.\n2. Pregnant or lactating women.\n3. Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment.\n4. Subjects on ECMO at start of IMP treatment.\n5. Suspected hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).\n6. Subjects discharged from hospital within the previous 14 days.\n7. Defined neutrophil counts up to one calendar day prior to start of IMP treatment.\n8. Defined platelet counts up to one calendar day prior to start of IMP treatment.\n9. Defined hemoglobin within up to one calendar day prior to start of IMP treatment.\n10. Pre-existing hemolytic disease.\n11. Thromboembolic events (TEEs) caused by other reasons than the current sCAP within 3 months before start of IMP treatment unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment.\n12. Severe renal impairment prior to start of IMP treatment.\n13. End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS).\n14. Pre-existing severe lung diseases concomitant to current sCAP (e.g. active tuberculosis, active lung cancer).\n15. Pre-existing decompensated heart failure.\n16. Pre-existing severe hepatic cirrhosis (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma.\n17. Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin \u002F placebo.\n18. Selective immunoglobulin A (IgA) deficiency with known antibodies to IgA.\n19. Life expectancy of less than 90 days, according to the investigator's clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions.\n20. Morbid obesity with high body mass index (BMI) ≥ 40 kg\u002Fm2, or malnutrition with low BMI \\\u003C 16 kg\u002Fm2.\n21. Treatment with polyvalent immunoglobulin preparations during the last 21 days before start of IMP treatment.\n22. Known treatment with predefined medications, during the last 2 days before start of IMP treatment.\n23. Hematopoietic stem cell transplantation or previous lung transplantation.\n24. Treatment with investigational medications\u002Fprocedures not according to SoC of the trial site, due to participation in another interventional clinical trial within 30 days before start of IMP treatment, or previous treatment with IMP in this clinical trial.",{"count":254,"type":21},590,[196],"The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV).\n\nOther objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.",[27],[259],"Severe Community-acquired Pneumonia","2026-03-30",{"date":262,"type":36},"2026-04-03",{"date":264,"type":36},"2023-09-09",{"date":266,"type":21},"2028-07-31",{"name":268,"class":269},"Biotest","INDUSTRY",147,{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":226,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":76},"100626978","frailty-and-outcomes-in-older-emergency-department-patients-with-pneumonia-100626978","NCT07442656","Frailty and Outcomes in Older Emergency Department Patients With Pneumonia","Impact of Clinical Frailty Scale on Morbidity and Mortality in Older Adults Diagnosed With Pneumonia in the Emergency Department: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥65 years\n* Clinical and radiological diagnosis of pneumonia in the emergency department\n* Ability to obtain informed consent from the patient or legal representative\n* Availability of a caregiver or relative able to describe baseline functional status\n\nExclusion Criteria:\n\n* Presentation with cardiopulmonary arrest or ongoing cardiopulmonary resuscitation at admission\n* Confirmed COVID-19 pneumonia\n* Inability to obtain reliable baseline functional history due to absence of an informant\n* Refusal to provide informed consent",{"count":279,"type":21},150,"Pneumonia is one of the leading causes of infection-related mortality in the older population. Traditional severity scores used in emergency departments, such as the Pneumonia Severity Index (PSI) and CURB-65, primarily focus on acute physiological derangements and may not adequately capture biological reserve and frailty in older adults. Frailty is a geriatric syndrome reflecting increased vulnerability to stressors and reduced recovery capacity.\n\nThis prospective observational cohort study aims to evaluate the predictive value of the Clinical Frailty Scale (CFS) for in-hospital mortality, 30-day mortality, and morbidity in patients aged 65 years and older presenting to the emergency department with pneumonia. Additionally, the study will assess whether incorporating frailty assessment into existing pneumonia severity scores improves prognostic accuracy.",[58,282,283],"Fraility","Hospitalizations",[282,285,286,287],"Clinical Fraility Scale","Older adults","Geriatric Emergency Medicine","2026-02-26",{"date":290,"type":36},"2026-03-02",{"date":292,"type":36},"2026-01-01",{"date":179,"type":21},{"name":295,"class":43},"Ege University",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100591878","comparing-antibiotic-treatment-strategies-for-children-with-pneumonia-in-outpatient-settings-stampp-100591878","NCT06986148","Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)","Comparing Antibiotic Treatment Strategies for Children With Community-Acquired Pneumonia in Outpatient Settings (Safety-Net Antibiotic Prescribing to Manage Pediatric Pneumonia [STAMPP])","STAMPP","Inclusion Criteria:\n\n* Aims 1 and 2:\n* Presenting with signs and symptoms of lower respiratory tract infection\n* Diagnosed with community-acquired pneumonia (CAP) by a clinician\n* The treating clinician intends to prescribe antibiotics for CAP, AND\n* Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.\n* Aim 3:\n* Parent\u002Fguardian of child enrolled in the trial, OR\n* Clinician who makes prescribing decision at the study site, OR\n* Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.\n\nExclusion Criteria:\n\n* Aims 1 and 2:\n* Hospitalization within the previous 7 days\n* Oxygen saturation below 90%, if measured\n* Incomplete immunization status (e.g., lacking at least 3 doses of the pneumococcal vaccines, typically given as part of the 2-, 4-, and 6-month vaccinations)\n* Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),\n* Substantially immunocompromised status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)\n* Receipt of oral or parenteral antibiotics within the previous 7 days\n* Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)\n* Known bacterial source of infection warranting immediate antibiotics\n* Pneumonia diagnosis within the previous 6 months, OR\n* Prior enrollment in the trial\n* Inability of the parent or guardian to speak English or Spanish\n* Aim 3:\n* Inability of the parent or guardian to speak English","12 Months","71 Months",{"count":307,"type":21},2000,[148],"The goal of this clinical trial is to determine if a \"watch and wait\" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are:\n\n* To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP)\n* To identify which patient groups benefit most from the SNAP strategy\n* To identify factors that shape implementation of each prescribing strategy.\n\nResearchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other.\n\nParticipants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.",[311,93],"Community Acquired Pneumonia (CAP)",[27,313,200,314,315],"Pediatric Respiratory Diseases","Antibiotic Use","SNAP","2026-01-24",{"date":318,"type":36},"2026-01-27",{"date":320,"type":36},"2025-09-09",{"date":322,"type":21},"2029-07-16",{"name":324,"class":43},"Ann & Robert H Lurie Children's Hospital of Chicago",4,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100620462","phase-1-early-inflammatory-immune-stratification-and-precision-glucocorticoid-intervention-in-acute-respiratory-failure-induced-by-community-acquired-pneumonia-100620462","NCT07357935","Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia","Inclusion Criteria:1. Age ≥ 18 years. 2. Admitted to the Intensive Care Unit (ICU) within 48 hours. 3. Meet diagnostic criteria for bacterial community-acquired pneumonia (CAP). 4. Meet at least one severity criterion: a) Receiving mechanical ventilation for acute respiratory failure with PEEP ≥ 5 cmH2O; OR b) On high-flow oxygen with FiO2 ≥ 0.5 and PaO2\u002FFiO2 ratio ≤ 250 mmHg; OR c) On a reservoir oxygen mask with PaO2 below the specified flow threshold (see protocol). 5. Signed informed consent.\n\n\\-\n\nExclusion Criteria: 1. Suspected aspiration pneumonia. 2. Invasive mechanical ventilation within 14 days prior to admission. 3. Diagnosis of hospital-acquired or ventilator-associated pneumonia (HAP\u002FVAP). 4. Positive for influenza virus, active tuberculosis, or fungal infection (except Pneumocystis jirovecii). 5. Active viral hepatitis or herpesvirus infection. 6. Hypersensitivity to glucocorticoids, or contraindications as judged by the investigator (e.g., severe concurrent infections, active gastrointestinal hemorrhage). 7. High-dose glucocorticoid therapy (\\>1 mg\u002Fkg\u002Fday prednisone equivalent) within 30 days for underlying disease. 8. Death within 24 hours of ICU admission. 9. Pregnancy or lactation. 10. Participation in other interventional studies or refusal to participate.\n\n\\-",{"count":333,"type":21},500,[335,336],"PHASE1","PHASE2","This is a prospective, multicenter, interventional cohort study aimed at constructing a high-quality, dynamic multimodal database for patients with acute respiratory failure caused by community-acquired pneumonia (CAP-ARF). The study focuses on bacterial CAP-ARF patients receiving standardized glucocorticoid therapy to investigate the heterogeneity of treatment responses under different etiologies and immune statuses. The goal is to provide a data foundation for precise immune stratification and identification of glucocorticoid-sensitive populations.",[339,58],"Acute Respiratory Failure","2026-01-14",{"date":342,"type":36},"2026-01-22",{"date":344,"type":21},"2026-02-01",{"date":346,"type":21},"2028-10-01",{"name":348,"class":43},"Qingyuan Zhan",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":356,"maxAge":18,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":76},"100617347","coenzyme-q10-in-pediatric-community-acquired-pneumonia-100617347","NCT07317440","Coenzyme Q10 in Pediatric Community-Acquired Pneumonia","Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia","Inclusion Criteria:\n\n* All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia\n\nExclusion Criteria:\n\n* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.","2 Months",{"count":358,"type":21},120,[148],"The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia",[93],"2025-12-18",{"date":364,"type":36},"2026-01-05",{"date":366,"type":21},"2025-12-31",{"date":368,"type":21},"2026-12-31",{"name":370,"class":43},"Tanta University",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":378,"maxAge":18,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100617202","efficacy-of-oral-nigella-sativa-as-adjuvant-therapy-in-children-with-moderate-persistent-asthma-100617202","NCT07315555","Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","Asthma","Inclusion Criteria:\n\n1. Children aged 6-18 years\n2. Diagnosed with moderate persistent asthma according to the Global Initiative for Asthma (GINA) 2022 guidelines\n3. Receiving stable standard controller therapy (inhaled corticosteroids ± long-acting β2-agonists) for at least 4 weeks prior to enrollment\n4. Able to perform reproducible spirometry\n\nExclusion Criteria:\n\n1. History of severe asthma exacerbation requiring ICU admission in the past 3 months\n2. Use of systemic corticosteroids within 4 weeks prior to enrollment\n3. Known hypersensitivity to Nigella sativa or its components\n4. Other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis)\n5. Significant comorbidities (e.g., cardiac, renal, or hepatic disorders)\n6. Inability to comply with study procedures","6 Years",{"count":380,"type":21},90,[148],"Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research",[93],[385,200,386],"Nigella sativa","Pediatric",{"date":388,"type":36},"2026-01-02",{"date":292,"type":21},{"date":391,"type":21},"2026-10-31",{"name":370,"class":43},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":423},"100538727","phase-3-clarithromycin-treatment-to-prevent-sepsis-progression-in-cap-react-100538727","NCT06294600","Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","Biomarker-Guided Early Elarithromycin Treatment to Prevent Sepsis Progression in Community-Acquired Pneumonia: The React Randomized Clinical Trial","REACT","Inclusion Criteria:\n\n* Age equal to or above 18 years\n* Male or female gender\n* In case of women of reproductive age, willingness to use dual contraceptive method during the study period\n* Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation\n* Community-acquired pneumonia (CAP)\n* Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and\u002For iv) pleuritic chest pain\n* PCT ≥0.25 ng\u002Fml\n* suPAR ≥6 ng\u002Fml\n\nExclusion Criteria:\n\n* Age below 18 years\n* Denial of written informed consent\n* Any stage IV malignancy\n* Any do not resuscitate decision\n* Patients necessitating non-invasive ventilation or mechanical ventilation\n* Hospitalization in Intensive Care Unit\n* Infection by SARS-CoV-2\n* Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg\u002Fkg prednisone for a period greater than the last 15 days\n* Intake of any macrolide for the current episode of CAP under study\n* Known infection by the human immunodeficiency virus\n* Any chronic anti-cytokine treatment for more than two months\n* QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome\n* Medical history of allergy to macrolides\n* Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation.\n* Medical history of torsades de pointes arrhythmia\n* Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation.\n* Concomitant presence of end-stage liver failure and end-stage renal failure.\n* Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored.\n* Any contradictions for macrolide uptake\n* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study\n* Participation in any other interventional trial within the last 30 days",{"count":402,"type":21},330,[196],"The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.",[27],[121,407,408,409,410,411,412,413],"CLARITHROMYCIN","SEPSIS","suPAR","PCT","ACCESS","SOFA","RSS","2025-12-15",{"date":416,"type":36},"2025-12-16",{"date":418,"type":36},"2024-02-12",{"date":420,"type":21},"2026-07-30",{"name":422,"class":43},"Hellenic Institute for the Study of Sepsis",24,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":434,"studyType":55,"phases":4,"briefSummary":435,"conditions":436,"keywords":441,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":76},"100614369","the-fever-clinic-acute-respiratory-cohort-100614369","NCT07278700","The Fever Clinic Acute Respiratory Cohort","The Fever Clinic Acute Respiratory Cohort (FACTS): A Prospective Real-World Cohort Study of Patients Presenting to Fever Clinics: Clinical Features, Laboratory and Radiographic Findings, and Long-Term Outcomes of Acute Respiratory Infections","FACTS","Inclusion Criteria:\n\n* Age ≥ 18 years (based on official identification document).\n* Presence of fever at the time of visit or within 24 hours prior to the visit, defined as a documented temperature of ≥37.3°C axillary\u002Ftympanic, ≥37.8°C orally, or ≥38.0°C rectally.\n* The primary cause of fever, as determined by the attending physician, is a respiratory tract infection.\n* Blood draw is required as part of standard clinical care.\n* Ability to comprehend the study's purpose, procedures, and potential risks, and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide independent informed consent due to impaired consciousness or other reasons.\n* Inability to comply with the study procedures.\n* Medical contraindications to blood sampling, such as severe coagulopathy (e.g., INR \\> 3.0, platelet count \\\u003C 50 × 10⁹\u002FL).\n* Diagnosed with a terminal illness (e.g., advanced malignancy, severe multiple organ failure) and a life expectancy of less than 3 months.",{"count":433,"type":21},1000,"30 Days","This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics. At enrollment, patients' clinical symptoms, laboratory findings, and chest imaging data will be collected. Longitudinal follow-up will be conducted to evaluate disease progression, complications, and long-term outcomes.\n\nAs an observational study, no interventions are involved; all patients receive routine clinical management as directed by their attending physicians. This real-world study design enables the assessment of the natural course of acute respiratory infections and the identification of factors associated with clinical outcomes.",[437,438,27,439,440],"Acute Respiratory Infections","Febrile Illnesses","Viral Respiratory Tract Infections","Influenza-like Illness",[442,443,58,444,445],"Respiratory Tract Infections","Fever","Anti-Bacterial Agents","Disease Progression","2025-12-11",{"date":448,"type":36},"2025-12-12",{"date":450,"type":36},"2025-10-10",{"date":452,"type":21},"2028-10",{"name":454,"class":43},"Fudan University",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":462,"maxAge":86,"enrollmentInfo":463,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":465,"conditions":466,"keywords":469,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":4},"100614444","clinical-predictors-of-severity-in-pediatric-community-acquired-pneumonia-at-assiut-university-childrens-hospital-100614444","NCT07279675","Clinical Predictors of Severity in Pediatric Community-Acquired Pneumonia at Assiut University Children's Hospital","CAP-Severity","Inclusion Criteria:\n\n* Children aged 1 month to 5 years.\n* Children of both sexes\n* Onset of illness in the community, not more than 48 hours after hospital admission.\n\nExclusion Criteria:\n\n* Children below 1 month, as neonatal pneumonia differs in pathology and management from CAP.\n* Children with hospital-acquired pneumonia\n* Known primary or secondary immunodeficiency\n* Children with chronic respiratory diseases (as cystic fibrosis, bronchiectasis) or congenital lung malformations.","1 Month",{"count":464,"type":21},67,"This study aims to identify the clinical factors that predict the severity of community-acquired pneumonia (CAP) in pediatric patients. Children admitted to Assiut University Children's Hospital with a diagnosis of CAP will be evaluated through clinical examination, vital signs, laboratory investigations, and radiological findings. The study focuses on determining which clinical features are associated with more severe disease, higher need for oxygen therapy, intensive care admission, or complications. Understanding these predictors may help clinicians recognize severe cases earlier and improve patient management and outcomes.",[58,467,468],"Pediatric Pneumonia","Lower Respiratory Tract Infection",[61,470,471],"Clinical risk factors","Hypoxemia","2025-12-10",{"date":448,"type":36},{"date":475,"type":21},"2025-12-01",{"date":477,"type":21},"2027-01-01",{"name":185,"class":43},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":501,"locationsCount":503},"100569056","physical-rehabilitation-of-older-persons-following-a-community-acquired-infection-hospitalization---a-randomised-controlled-trial-100569056","NCT06689280","Physical Rehabilitation of Older Persons Following a Community-Acquired Infection Hospitalization - A Randomised-Controlled Trial","Physical Rehabilitation of Older Persons Following a Community-Acquired Infection Hospitalization: A Feasibility Study","REHAB-CAI","Inclusion Criteria:\n\n* Patients aged ≥65 years or 18-64 years if the presence of at least one chronic disease (e.g., diabetes, COPD, heart failure, etc.)\n* Suspicious of a lower respiratory tract infection AND\n* Presence of one or more symptoms of a lower respiratory tract infection such as fever ≥38.3°C, hypothermia \\\u003C35.0°C, new onset of cough, pleuritic chest pain, dyspnea, or altered breath sounds on auscultation.\n* Positive urine nitrate test and\u002For leukocyturia as depicted by positive esterase test or microscopy AND\n* Presence of one or more symptoms of urinary tract infection such as dysuria, urgent or frequent urination, perineal or suprapubic pain, costo-vertebral tenderness or flank pain, fever (ear or rectal temperature of ≥38.2°C or axillary temperature of ≥38.0°C), or history of feeling feverish with shivering or rigors in the past 24 hours.\n* Functionally independent before hospitalization and expected to be discharged to their own homes.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Hospitalization within the past 14 days.\n* Inability to participate in the study due to dementia, paralysis, or other disorders.\n* Severe aortic valve stenosis or terminal illness.\n* Unstable cardiac arrhythmic disease.\n* High risk for non-adherence as determined by screening evaluation.\n* Already participating in regular exercise training.\n* Unable to understand Danish.\n* Unwilling or unable to give informed consent.",{"count":488,"type":21},460,[148],"Community-acquired infections such as community-acquired pneumonia (CAP) and urinary tract infection (UTI) remain leading causes of hospitalization and death due to infections in older persons in Europe. Hospitalization often results in further disabilities and frailty for older and frail individuals, from which some may never recover. Physical activity is well-established as a cornerstone in the primary prevention and treatment of several noncommunicable diseases. However, there is currently no established rehabilitation model following a pneumonia or other infection, nor is there any evidence to support the impact of rehabilitation on the mental and physical health of older and frail individuals following a pneumonia hospitalization or other infection.\n\nThe aim of the feasibility study is to evaluate a patient-centered and individualized exercise intervention that is kick-started during hospitalization and continued for 3 months after discharge with video-supervised home-based exercise training to patients hospitalized with CAP or UTI compared to standard care with regard to safety, clinical outcomes, patients' perception, functional ability, organizational aspects, and economic aspects.",[27,492],"Urinary Tract Infections",[121,494],"UTI","2025-11-26",{"date":497,"type":36},"2025-12-02",{"date":292,"type":21},{"date":500,"type":21},"2029-12-31",{"name":502,"class":43},"Nordsjaellands Hospital",3,{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":533},"100526419","phase-3-acyclovir-in-ventilated-patients-with-pneumonia-and-hsv-1-in-bal-100526419","NCT06134492","Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL","Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage","HerpMV","Inclusion Criteria:\n\n1. ≥ 18 years\n2. need for invasive or non-invasive respiratory support\n3. PCR HSV-1 detection in BAL (≥ 10\\^3 copies\u002Fml)\n4. Pneumonia (community or healthcare acquired, incl. ventilator-associated pneumonia)\n5. declaration of consent by the patient or legal representative\n\nExclusion Criteria:\n\n1. History of hypersensitivity to acyclovir or valacyclovir or other components of the investigational product.\n2. Pregnancy\u002FLactation\n3. Simultaneous participation in another interventional clinical trial\n4. Decision to withhold life-sustaining therapies\n5. Use of a virostatic agent (i.v. or p. os) with activity against herpes simplex (acyclovir, valacyclovir, famciclovir\u002Fpenciclovir, brivudine, cidofovir, foscarnet) for therapeutic or prophylactic reasons at the time of randomization.\n6. Solid organ transplantation, stem cell transplantation\n7. Neutropenia (absolute neutrophil count \\\u003C1500\u002Fμl (\\\u003C1.5 × 109 \u002Fl)\n8. Previous study participation in HerpMV",{"count":513,"type":21},616,[196],"Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her\u002Fhis life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, such as meningitis. In almost every second mechanically ventilated patient in intensive care who has pneumonia, HSV can be detected in the respiratory tract. This is caused by reactivation of the viruses as a result of the severe underlying disease and stress during intensive care therapy. Whether treatment of the herpes viruses (e.g. with acyclovir) is necessary in this situation and helps the patients to cure has not been clarified, especially as acyclovir can also cause side effects such as a deterioration in kidney function. Currently, the physicians decide to treat the herpes viruses in about half of the patients. Several studies have shown that patients for whom the physician decided to treat the viruses survived more often. However, all of these studies looked at the course of the disease only retrospectively and thus are subject to many biases (including physician selection of who receives treatment, missing data). A definitive conclusion as to whether herpesvirus therapy can be recommended cannot be drawn without doubt from these studies. Therefore, the investigators would like to investigate in a randomized controlled trial, i.e. patients are randomly assigned to the experimental (therapy of herpesviruses) or control group (no therapy of herpesviruses), the effect of therapy with acyclovir on survival in ventilated intensive care patients with lower respiratory tract infection (pneumonia) in whom a large amount of HSV was found in the respiratory tract. The goal of the study is to provide clarity on whether therapy will help patients recover.",[517,518,27,519,520],"Pneumonia, Viral","Ventilator Associated Pneumonia","Herpes Simplex","Hospital-acquired Pneumonia",[200,519,522,523],"Mechanical Ventilation","Aciclovir","2025-11-18",{"date":526,"type":36},"2025-11-21",{"date":528,"type":36},"2024-02-20",{"date":530,"type":21},"2026-12",{"name":532,"class":43},"Jena University Hospital",28,{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":76},"100538767","phase-4-the-optimal-antibiotic-treatment-duration-for-community-acquired-pneumonia-in-adults-diagnosed-in-general-practice-in-denmark-cap-d-100538767","NCT06295120","The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)","The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark: an Open-Label, Pragmatic, Randomised Controlled Trial","CAP-D","Inclusion Criteria:\n\nEligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics.\n\nExclusion Criteria:\n\n1. Need for immediate hospitalisation at the time of diagnosis.\n2. Known allergy to beta-lactam antibiotics.\n3. Any coinfection necessitating antibiotic treatment.\n4. Use of systemic antibiotics or antivirals within the last month.\n5. Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer).\n6. Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder).\n7. Pregnant or lactating.\n8. Patients not capable of consenting and\u002For patients deemed non-suitable for participation by the healthcare professional.",{"count":543,"type":21},600,[24],"The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice.\n\nEligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics.\n\nConsenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.",[27],[61,548,549,550],"Treatment duration","Phenoxymethylpenicillin","General Practice","2025-08-15",{"date":553,"type":36},"2025-08-17",{"date":555,"type":36},"2023-11-13",{"date":557,"type":21},"2026-03-31",{"name":559,"class":43},"Research Unit for General Practice in Aalborg",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":4},"100601347","a-validation-study-on-a-prognostic-prediction-model-for-respiratory-tract-infections-100601347","NCT07109310","A Validation Study on a Prognostic Prediction Model for Respiratory Tract Infections","A Prospective, Single-Center Clinical Validation Study of Transcri Ptomics-Based Biomarkers for Predicting Respiratory Infection Progression and Prognosis","Inclusion Criteria:\n\nCommunity-acquired pneumonia group\n\n* Age ≥18 years old;\n\n  * Sign the informed consent form; ③ According to the researcher's judgment, be able to comply with the research visit; ④ Comply with the diagnostic criteria for community-acquired pneumonia in the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults (2016 Edition); ⑤ The time from onset to enrollment was ≤8 days. Sepsis Group\n* Age ≥18 years old;\n\n  * Sign the informed consent form; ③ According to the researcher's judgment, be able to comply with the research visit;\n\n    * Patients who meets the sepsis 3.0 diagnostic criteria.\n\nExclusion Criteria:\n\nExclusion criteria\n\n* Respiratory failure related to underlying heart and lung diseases;\n\n  * Severe liver and kidney dysfunction, pregnancy or lactation period;\n\n    * Meet the indications for organ transplantation or have undergone organ transplantation surgery in the past; ④ Known HIV infection; ⑤ Screening: Those who have experienced unstable angina pectoris or myocardial infarction within 30 days prior to the screening and have not received vascular recanalization treatment, as well as those with extensive cerebral hemorrhage; ⑥ Situations where researchers determine that enrollment is not appropriate.","80 Years",{"count":279,"type":21},"This study adopted a prospective, single-center, open-label design, aiming to evaluate the efficacy of the RTI clinical outcome prediction model in predicting clinical outcomes in subjects with acute respiratory tract infections.\n\nIn this study, the subjects were divided into the community-acquired pneumonia group and the sepsis group, including one baseline visit, one visit on the 7th day, and one visit on the 28th day.\n\nDuring the research process, blood samples will be collected at the corresponding visiting points for the validation of the predictive model.",[571,572,93,573],"Sepsis","Acute Respiratory Distress Syndrome","Transcriptome","2025-07-31",{"date":576,"type":36},"2025-08-07",{"date":551,"type":21},{"date":579,"type":21},"2026-12-30",{"name":581,"class":43},"Peking Union Medical College Hospital",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":121,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":607},"100560470","phase-2-efficacy-and-safety-of-sr1375-in-adult-patients-with-cap-100560470","NCT06577558","Efficacy and Safety of SR1375 in Adult Patients With CAP","A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia","Key Inclusion Criteria:\n\n* The subject or their legally acceptable representative (LAR) has voluntarily signed the informed consent form (ICF) prior to any study-related procedures, and the subject is willing and able to comply with all study requirements, restrictions, and procedures. If consent is provided by an LAR for a subject with limited or no capacity to consent, re-consenting may be performed if the subject regains capacity.\n* Aged 18 to 85 years.\n* Diagnosis of CAP\n* Prior to screening, the subject has been receiving standard-of-care treatment for pneumonia in a medical institution, including at least 3 days of intravenous (IV) anti-infective therapy, with no clinical improvement.\n* Chest CT showing multi-lobar infiltrates, and for subjects not receiving invasive mechanical ventilation, an oxygenation index (PaO2\u002FFiO2 ratio) between 100 and 300 mmHg.\n* Expected to require continued hospitalization for at least 7 days from the time of signing the ICF.\n* Baseline NIAID-OS 8-point scale score of 5 points and transcutaneous oxygen saturation ≤ 93% without oxygen inhalation, 6 points or 7points. (5 points refer to hospitalization with oxygen therapy; 6 points refer to hospitalization with high flow oxygen therapy or non-invasive mechanical ventilation. 7 points refer to hospitalization with invasive mechanical ventilation).High oxygen flow refers to ≥ 4 L\u002Fmin.)\n* With ≥ 1 high risk factors including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, type 2 diabetes, chronic kidney disease, coronary heart disease, age ≥ 65 years, moderate obesity (body mass index\\>32.5kg\u002Fm2), etc.\n* Participants of women of childbearing potential(WOCBP) and male participants with WOCBP partners must agree to use one or more effective contraceptive methods during the treatment period and until 90 days after the last administration.\n\nKey Exclusion Criteria:\n\n* Patients who are currently receiving or are expected to require ECMO treatment within 24 hours.\n* Presence of active tuberculosis (TB) or severe asthma.\n* History of unstable angina or acute myocardial infarction within 3 months prior to screening, or stroke within 4 weeks prior to screening.\n* Received chemotherapy and\u002For immunotherapy for a malignant tumor within 4 weeks prior to randomization, or are planned to receive such treatment during the study period; presence of a hematological malignancy not in complete remission; or a lung tumor with concurrent obstructive pneumonia.\n* Presence of any concomitant disease that is expected to result in death within 12 weeks after randomization.\n* Prior use of JAK inhibitors (e.g., Baricitinib), interleukin receptor inhibitors (e.g., Tocilizumab), or any investigational drug in another clinical trial, where the last dose was administered less than 5 half-lives before the first dose of the study drug in this trial.\n* ALT) or AST \\> 3 times the upper limit of normal (ULN).\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula); however, patients undergoing dialysis may be included upon the investigator's assessment of their suitability for the trial.\n* Presence of clinically significant abnormalities on ECG that may seriously affect subject safety, e.g., QTcF \\> 480 ms.\n* Female subjects who are pregnant, lactating, or have a positive serum β-HCG pregnancy test.\n* Presence of any severe systemic disease or clinical condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.","85 Years",{"count":591,"type":21},240,[336],"This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.",[27],[596,597],"Community acquired Pneumonia","SR1375","2025-07-07",{"date":600,"type":36},"2025-07-09",{"date":602,"type":36},"2024-09-10",{"date":604,"type":21},"2025-10-30",{"name":606,"class":269},"Shanghai SIMR Biotechnology Co., Ltd.",29,{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":615,"sex":17,"minAge":85,"maxAge":18,"enrollmentInfo":616,"targetDuration":4,"studyType":22,"phases":618,"briefSummary":619,"conditions":620,"keywords":621,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":631,"locationsCount":76},"100288169","phase-2-twice-daily-treatment-with-amoxicillin-for-non-severe-community-acquired-pneumonia-100288169","NCT03031210","Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.","Treatment of Non-severe Community Acquired Pneumonia With Twice Daily Compared to Thrice Daily Regimen- A Non-inferiority Pragmatic Randomized-controlled Trial.","Inclusion Criteria:\n\n* All patients 3 months to 18 years of age attending the pediatric ED and diagnosed with a non-severe pneumonia, will be considered for enrolment. More precisely, the following inclusion criteria will be required:\n\n  1. Presence of respiratory symptoms (cough and\u002For dyspnea)\n  2. Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles)\n  3. Presence of fever\n  4. Positive chest radiography as interpreted by the treating physician\n\nExclusion Criteria:\n\n* Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abcess or pneumatocoele)\n* History of anaphylactic or allergic reaction to penicillin or amoxicillin according to the treating physician.\n* History of a serious nonimmunoglobulin E-mediated reactions (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis) attributed to amoxicilin.\n* Caregiver unable to provide consent (language barrier or lack of caregiver presence)\n* Underlying unstable chronic illness (ie. cystic fibrosis, immune suppression, active tuberculosis, bronchiectasis or active pulmonary malignancies)\n* Persistent\u002Fchronic pneumonia syndromes (with symptoms for \\>2 weeks), suspected by the physician to be caused by atypical pathogens, hospital- acquired pneumonia (been hospitalized within 2 weeks prior to enrolment), aspiration pneumonia or recurrent pneumonias.\n* Any history of receiving amoxicillin within the past month\n* Need hospitalisation for any other reasons (ie. persistent vomiting, severe life-threatening infection such as septicaemia or meningitis requiring intravenous antimicrobial agents)\n* Previous participation in study",true,{"count":617,"type":21},1370,[336,196],"The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).",[27],[622,623,624],"Non-severe community-acquired pneumonia","Amoxicillin treatment","Twice daily antibiotic regimen","2025-05-13",{"date":627,"type":36},"2025-05-14",{"date":629,"type":36},"2017-06-11",{"date":104,"type":21},{"name":632,"class":43},"St. Justine's Hospital",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":76},"100529176","high-dose-inhalations-of-nitric-oxide-in-the-treatment-of-pneumonia-100529176","NCT06170372","High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia","The Effectiveness of Adding Multiple Intermittent High-dose Inhalations of Nitric Oxide to Standard Antibacterial Therapy in the Treatment of Pneumonia","Inclusion Criteria:\n\n1. An established diagnosis of Nosocomial Pneumonia (NP) after cardiac surgery under cardiopulmonary bypass (CPB) or hospitalization for Community-acquired pneumonia (CAP).\n2. Spontaneous breathing.\n3. Age \\> 18 years.\n4. Signed informed consent.\n5. Negative result of immunochromatographic Severe acute respiratory syndrome-related coronavirus 2 rapid antigen test on the day of diagnosis of pneumonia.\n\nDiagnostic criteria for NP The diagnosis of NP is considered established when the number of points on the\n\nClinical Pulmonary Infection Score (CPIS) is greater than 6:\n\nDiagnostic criteria for CAP:\n\nRadiologically confirmed focal pulmonary opacity and at least 2 clinical symptoms and signs of the following:\n\n1. acute fever at the onset of the disease (t° \\> 38.0°C);\n2. cough with sputum;\n3. physical signs (crepitus\u002Ffine rales, bronchial breathing, shortening of percussion sound);\n4. leukocytosis \\> 10x109\u002Fl and\u002For left shift (\\> 10%)\n\nExclusion Criteria:\n\n1. Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, infective endocarditis etc.).\n2. Mechanical ventilation\n3. Presence of tracheostomy\n4. Patient's participation in another clinical trial at the time of screening or within the previous 3 months.\n5. Concomitant pulmonary disease with the need for respiratory support before the development of pneumonia.\n6. History of malignancy or other irreversible diseases\u002Fconditions with a life expectancy of less than 1 year.\n7. Presence of HIV infection",{"count":54,"type":21},[148],"This is a multicenter, prospective randomized controlled trial. At least 2 but no more than 5 centers are expected to participate in the study.\n\nThe primary objective is to test the hypothesis that the addition of high-dose inhaled nitric oxide therapy to standard treatment has a positive effect on the clinical course of pneumonia and the structure and function of cardiopulmonary system.\n\nNumber of participants: 200, including the subproject NO-PNEUMONIA-CAP - 100 CAP participants, the subproject NO-PNEUMONIA-NP - 100 NP participants.\n\nNumber of groups: 4 Inhalation of iNO at a dose of 200 ppm for 30 minutes under the control of methemoglobin level (no more than 5%) three times a day if the patient is allocated to the main group. The general course of iNO therapy will last until the pneumonia resolves, but no more than 7 days. Recording of vital signs and safety assessment will be carried out immediately before the initiation of NO therapy and every 15 minutes after its start (pulse, blood pressure, respiratory rate, SpO2, temperature, MetHb level).",[644,27],"Nosocomial Pneumonia","2025-04-07",{"date":647,"type":36},"2025-04-10",{"date":649,"type":36},"2024-01-15",{"date":651,"type":21},"2027-01-15",{"name":653,"class":43},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":661,"targetDuration":4,"studyType":22,"phases":663,"briefSummary":664,"conditions":665,"keywords":666,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":76},"100508663","phase-3-customized-antibiotic-treatment-duration-among-hospitalized-patients-with-moderately-severe-community-acquired-pneumonia-100508663","NCT05903352","Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia","CAT-CAP","Inclusion Criteria:\n\n* Adult patient (≥18 years old)\n* Admitted to hospital for suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:\n\n  * Fever (temperature \\> 38°C) or hypothermia (\\\u003C 36°C)\n  * Dyspnea\n  * Cough\n  * Production of purulent sputum\n  * Crackles\n* Radiological evidence of a new infiltrate (chest X-ray or CT scan)\n* Negative viral respiratory testing\n* Treated for a minimum of 48 hours with antibiotics (excluding azithromycin due to its prolonged half-life)Presenting with an early clinical response within the last 24 hours (up to 7 days after the start of antibiotic treatment, if planned treatment duration \\> 7 days), defined by the presence of all the following criteria:apyrexia (T°C ≤ 37.8)heart rate \\\u003C 100\u002Fminrespiratory rate \\\u003C 24\u002Fmin, according to the patient's usual mode of oxygenation,arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,Patient currently under antibiotic treatment for his suspected CAP (i.e. the last dose of ATB has been administered to the patient less than 24 hours ago)\n* Patient presenting a clinical response within the last 24 hours defined by the presence of all the following criteria:\n\n  * apyrexia (T°C ≤ 37.8)\n  * heart rate \\\u003C 100\u002Fmin\n  * respiratory rate \\\u003C 24\u002Fmin, according to the patient's usual mode of oxygenation,\n  * arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,\n  * systolic blood pressure ≥ 90mmHg, The last occurring of these criteria must have appeared within the last 24 hours.\n* The antibiotic treatment for suspected CAP has started at least 48 hours ago and at most 6 days ago\n* No other site of infection besides respiratory\n* Affiliated to Health insurance\n* Has given informed consent\n* Patient understanding oral and written French, or presence of a relative who can explain and help him complete the study documents\n\nExclusion Criteria:\n\n* Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)\n* Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4\\\u003C200\u002Fmm3)\n* Suspected or confirmed legionellosis\n* Any other infection necessitating concomitant antibiotic treatment\n* Confirmed or suspected aspiration pneumonia or healthcare-associated pneumonia\n* Treatment of suspected CAP with azithromycin (due to its prolonged half-life)\n* Concomitant steroid treatment (only for patients treated with fluoroquinolones antibiotics)\n* Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, uncontrolled arterial hypertension, atherosclerosis (only for patients treated with fluoroquinolones antibiotics)\n* Pregnant or breastfeeding woman\n* Life expectancy \\\u003C 1 month\n* Patient under legal guardianship (French \"tutelle\" or \"curatelle\")\n* Patient without fixed address\n* Patient enrolled in another interventional clinical trial on CAP treatment",{"count":662,"type":21},328,[196],"The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is non-inferior to the efficacy of standard antibiotic duration in CAP patients treated in the hospital setting.\n\nAs the secondary objectives, the study aims\n\n* To study if the efficacy of our experimental strategy on antibiotic treatment duration compared to standard of care in CAP patients treated in the hospital setting is non-inferior in terms of:\n\n  * Persistence of cure at Day 30 of antibiotic treatment\n  * All-cause mortality rate on Day 30 of antibiotic treatment\n  * Patients evolution of pneumonia symptoms and quality of life via 2 scores (CAP score, CAP Sym) at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7 , at Day 15, and at Day 30 of antibiotic treatment.\n* To compare between the 2 study arms at Day 30 of antibiotic treatment:\n\n  * The duration of antibiotic treatment;\n  * The length of hospital stay;\n  * The frequency and severity of adverse events during the 30 days after the start of treatment.\n* To explore the impact of reduced antibiotic treatment duration for CAP on the oropharyngeal resistome.",[58],[58,667,668,669],"Antibiotic treatment duration","Antibiotic resistance","Infectious diseases","2025-03-17",{"date":672,"type":36},"2025-03-20",{"date":674,"type":36},"2024-02-05",{"date":676,"type":21},"2027-05",{"name":678,"class":43},"Assistance Publique - Hôpitaux de Paris"]